Drug Trial Radar · NCT05908409
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Last checked: Nov 19, 2026Latest source record: May 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
37
Planned (sponsor's estimate)
Start
Jun 5, 2023
Primary completion
Dec 22, 2025
Study completion Mar 22, 2026
Sponsor
- Lead sponsor
- IDP Discovery Pharma S.L.Industry
- Sponsor type
- Industry
- First posted
- Jun 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aims of this 2-part study are: * Phase I: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple myeloma (MM), diffuse large B cell lymphoma not otherwise specified (DLBCL-NOS), high-grade B cell lymphoma with double or triple hit rearrangement (HGBL-DH/TH) and HGBL-NOS, and chronic lymphocytic leukemia (CLL). * Phase II: To evaluate the overall response rate (ORR), duration of response (DoR), time to progression (TTP), progression-free survival (PFS), event-free survival (EFS) and Overall survival (OS), in patients with MM, DLBCL-NOS, HGBL-DH/TH, HGBL-NOS or CLL treated with IDP-121 at the recommended Phase 2 Dose (RP2D).
Conditions
- Multiple Myeloma (MM)
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Double Hit Lymphoma
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- Chronic Lymphocytic Leukemia (CLL)
- Triple Hit Lymphoma
Interventions
IDP-121Drug
IDP-121 is a new chemical entity specifically designed to directly target cMyc protein that has demonstrated activity in multiple liquid and solid tumor cell lines and preclinical animal models
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Dose EscalationTime frame: Through 1 treatment cycle (each cycle is 28 days)
- Phase 1: Dose EscalationTime frame: Through 12 treatment cycles (each cylce is 28 days) or until End of Treatment, whatever occurs first
- Phase 2: Expansion PhaseTime frame: Based on iwCLL 20181, IMWG 20162, and the Lugano 20143 criteria for CLL, MM and Lymphomas, respectively; assessed at the end of study (12 months)
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Hospital Universitari Vall d'hebron
Barcelona, Spain · Recruiting
Hospital Durán i Reynals - ICO L´Hospitalet
Barcelona, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Hospital Universitario La Paz
Madrid, Spain · Recruiting
Hospital Universitario Puerta de Hierro
Madrid, Spain · Recruiting
Hospital Clínico Universitario Virgen de la Arrixaca
Murcia, Spain · Recruiting
Hospital Universitario Virgen del Rocio
Seville, Spain · Recruiting
Hospital de Clinico Universitario de Valencia
Valencia, Spain · Recruiting
Hospital Universitario Miguel Servet
Zaragoza, Spain · Recruiting
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, Spain · Recruiting
Hospital Universitario de Salamanca
Salamanca, Castille and León, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.